The American College of Rheumatology (ACR) just unveiled a new guideline summary for the treatment of systemic lupus erythematosus (SLE). The new guidelines are targeted at children and adults with SLE, with the objectives of achieving and maintaining low-level disease activity, reducing mortality and morbidity, and minimizing treatment-related toxicities. 

The ACR universally recommends using hydroxychloroquine, minimizing glucocorticoid exposure, and the early introduction of conventional and/or biologic immunosuppressive therapies. Additionally, the following good practice statements are provided:

Comorbidities and Risk Management
  • All people with SLE should receive screening, monitoring, and management for comorbid conditions associated with SLE and its therapies (including infection, cardiovascular disease, bone and joint damage, malignancy, reproductive health complications, and presence of antiphospholipid antibodies.

Medication Guidance and Treatment Goals

  • The goal of SLE treatment should be optimal control of disease (e.g., remission or a low level of disease activity) to improve long-term clinical outcomes.
  • Prescribe glucocorticoids promptly to obtain rapid control of acute inflammation using the lowest dose and shortest duration necessary and initiate immunosuppressive therapy early to minimize glucocorticoid-related toxicity.

General Treatment Strategies

  • People with active SLE symptoms should be diagnosed and treated promptly, with severity of lupus activity guiding intensity and choice of therapy.
  • When multiple organ systems are involved at onset or during a flare of SLE, therapy should be directed toward all manifestations but should prioritize areas at greatest risk for irreversible damage.
  • Organ- or life-threatening SLE should be treated urgently/emergently with aggressive therapy (e.g., pulse/high-dose glucocorticoid and immunosuppressive therapy), including consideration of combination therapies, as time may not permit sequential therapy; the clinical situation and patient’s preference should guide the specific combination therapy.
  • When medications, procedures, and surgeries beyond the scope of rheumatology practice are considered, the decision to proceed with such therapies requires multidisciplinary discussion between the rheumatologist and the relevant specialists/proceduralists/surgeons.
  • When clinical or serologic findings suggest an additional diagnosis or overlap with SLE (e.g., aquaporin-4 antibodies in setting of known SLE and new onset transverse myelitis or optic neuritis), therapy should be adjusted if necessary, depending upon which process is predominant and in consultation with the relevant specialist(s).

Cutaneous/mucocutaneous

  • People with SLE should be educated on the use of sunscreen and other sun-protection measures to reduce risk of rash and potential disease flare.
  • Initial therapy for cutaneous lupus rash—in addition to HCQ—should be topical, including glucocorticoid and/or calcineurin inhibitors; initial therapy may also include a course of intralesional glucocorticoid with dermatology and/or a brief, limited course of oral glucocorticoid.

Musculoskeletal

  • Initial therapy for acute or recurrent episodes of inflammatory arthritis in people with SLE may include a course of NSAID or a limited course of oral glucocorticoid while waiting for recommended long-term therapies to take effect.

View the complete summary for more information regarding the recommendations, their strength rating and related level of evidence. The full manuscript should follow at a later date in Arthritis & Rheumatology and Arthritis Care and Research, so be sure to sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2025 Guideline Central, all rights reserved.